文献速递心力衰竭与心肌病血脂与心血管预防

恰加斯心肌病与其他病因射血分数降低心衰的预后比较

Comparative Prognosis of Chagas and Other Cardiomyopathies.
PubMed 文献 · J Am Coll Cardiol · 2026-03-16

本研究基于ATMOSPHERE、PARADIGM-HF和GALACTIC-HF三项试验中23647例HFrEF患者,比较恰加斯病与其他病因的临床结局。恰加斯HFrEF的全因死亡、心血管死亡、心衰住院及卒中发生率均最高,较缺血性病因的校正风险显著升高。

要点

  • 恰加斯HFrEF较缺血性病因的复合终点风险显著升高(校正HR 1.65)。
  • 恰加斯HFrEF的卒中风险较缺血性病因升高逾一倍(校正HR 2.16)。
  • 恰加斯病因与心衰住院、心血管死亡和全因死亡风险升高独立相关。

核心结论

  • 恰加斯HFrEF具有独特的临床病程,不仅死亡风险增加,卒中风险也高于其他病因(瓣膜性和「其他」病因除外)。

研究设计与样本

  • 基于ATMOSPHERE、PARADIGM-HF和GALACTIC-HF三项试验的回顾性比较分析,共纳入23647例HFrEF患者。
  • 病因由研究者报告并分类为缺血性、瓣膜性、酒精性、高血压性、特发性、病毒性、恰加斯病或「其他」。
  • 采用Cox模型分析结局,校正基线特征、患者设置、试验及其他潜在混杂因素。

主要发现

  • 23647例患者中缺血性13381例、特发性4344例、高血压性2559例、其他1923例、酒精性423例、瓣膜性412例、病毒性297例、恰加斯病308例。
  • 恰加斯HF较其他病因的所有临床结局发生率最高。
  • 较缺血性病因,恰加斯HF的复合终点校正HR为1.65(95%CI 1.36-2.02)。
  • 较缺血性病因,恰加斯HF的心衰住院校正HR为1.75(95%CI 1.36-2.25),心血管死亡校正HR为1.86(95%CI 1.47-2.35)。
  • 较缺血性病因,恰加斯HF的全因死亡校正HR为1.82(95%CI 1.47-2.25),卒中校正HR为2.16(95%CI 1.20-3.88)。

临床怎么用

  • 对恰加斯HFrEF患者应关注其高于其他病因的死亡和卒中风险,加强相应监测与管理。

局限性

  • 病因由研究者报告,可能存在分类偏倚。
  • 分析基于三项临床试验人群,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chagas disease, caused by Trypanosoma cruzi parasites, is a common cause of heart failure (HF) in Latin America and has recently been declared endemic in the United States. The authors compared outcomes in Chagasic HF vs ischemic and other nonischemic etiologies of HF with reduced ejection fraction (HFrEF). OBJECTIVES: The aim of this study was to compare clinical outcomes of Chagasic HFrEF vs ischemic and other nonischemic etiologies. METHODS: Investigator-reported etiology of HFrEF in the ATMOSPHERE, PARADIGM-HF, and GALACTIC-HF trials was categorized as ischemic, valvular, alcoholic, hypertensive, idiopathic, viral, Chagasic, or "other." Time to the composite of first HF hospitalization or cardiovascular death, its components, all-cause death, and stroke was analyzed using Cox models adjusted for baseline characteristics, patient setting, trial, and other potential confounders. RESULTS: Among 23,647 patients (13,381 ischemic, 4,344 idiopathic, 2,559 hypertensive, 1,923 others, 423 alcoholic, 412 valvular, 297 viral, and 308 Chagasic), Chagasic HF had the highest incidence rates of all clinical outcomes compared with other etiologies. Compared with patients with ischemic etiology, the adjusted HRs in Chagasic HF were significantly higher for the composite outcome (HR: 1.65; 95% CI: 1.36-2.02), HF hospitalization (HR: 1.75; 95% CI: 1.36-2.25), cardiovascular death (HR: 1.86; 95% CI: 1.47-2.35), all-cause death (HR: 1.82; 95% CI: 1.47-2.25), and stroke (HR: 2.16; 95% CI: 1.20-3.88). CONCLUSIONS: Patients with Chagasic HFrEF have a distinct clinical course associated not only with excess mortality but also with an increased risk for stroke compared with other etiologies except for valvular and "other" etiologies. (Aliskiren Trial to Minimize Outcomes in Patients with Heart Failure [ATMOSPHERE], NCT00853658; Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] with ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial [PARADIGM-HF], NCT01035255; Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure [GALACTIC-HF], NCT02929329).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Ono R, Docherty KF, Henderson AD, et al. Comparative Prognosis of Chagas and Other Cardiomyopathies. J Am Coll Cardiol. 2026. PMID: 41847775. doi:10.1016/j.jacc.2026.03.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。